In the treatment of prostate cancer the first very expensive drug we had that was FDA approved was Provenge, with an initial cost of $93,000 for a one-month’s treatment protocol. Today, the cost is in excess of $106,000. According to the phase III clinical trial result Provenge extends life by a median of 4.1 months, [...]
Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). The last few years has seen the development of new drugs that extend the survival of men. Because of these [...]
According to Malecare, Prostate Cancer kills Black men as a rate that is 2.4 times that for White men. According to the Men’s Health Foundation Ghana “1 in 5 Ghanaian men will get prostate cancer in their lifetime.”(1) The Prostate Cancer UK also said “1 in 4 black men will get prostate cancer in their [...]